AzTrials
AzTrials

Esophageal DiseaseFREGATNCT02526095

The French EsoGastricTumours Data Base

An observational study of Esophageal Disease, run by University Hospital, Lille at 31 sites in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Esophageal Disease
How many people
15,000 participants
Where
31 sitesFrance
Study dates
Jun 2014to May 2027
How long will I take part?
13 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients with gastroesophageal cancer diagnosed and treatment-naïve, if not receiving neoadjuvant treatment in a participating center will be included after acceptance and signature of consent, whether operated or not, whatever histologic type, tumor stage, and the therapeutic strategy.

Who may be able to join

  • esophageal cancer, gastric or gastroesophageal junction diagnosed biopsy , regardless of the subtype of cancer, tumor stage or treatment envisaged.
  • Naive treatment for this cancer,
  • Naive treatment for this cancer , failing that received neoadjuvant treatment ,
  • Male or female ≥ 18 years.
  • social protection scheme .
  • sign a free and informed consent for blood sampling , the different questionnaires and the collection of patient information.

Who cannot join

  • Male or female aged ( e) under 18 years.
  • Private person of liberty or under supervision (including guardianship ) .
  • People who do not speak French.
  • Major Nobody unable to consent .
  • Patient FREGAT already included in the base.
  • Patient Refusal .

Trial locations and contacts

31 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Guillaume Piessen, MD, PhD contact

+3320444407

guillaume.piessen@chru-lille.fr

31 sites in 1 country

France31 sites, 31 recruiting

  • Chu Amiens Picardie

    Amiens

    Recruiting

  • Chru Besancon

    Besançon

    Recruiting

  • Hu Paris Site Avicenne Aphp

    Bobigny

    Recruiting

  • Chu de Caen Normandie

    Caen

    Gilles Lebreton, MD, PhD

    Recruiting

  • Crlcc Francois Baclesse

    Caen

    Marie-Pierre Galais, MD,PhD

    Recruiting

  • Hopital Estaing - Chu63 - Clermont Ferrand

    Clermont-Ferrand

    Recruiting

  • Hu Paris Nord Site Louis Mourier Aphp

    Colombes

    Recruiting

  • Hopital Le Bocage Chru Dijon

    Dijon

    Recruiting

  • Chu de Grenoble Alpes

    Grenoble

    Recruiting

  • Hop Claude Huriez Chu Lille

    Lille, 59045

    guillaume Piessen, MD, PhD

    Recruiting

  • Clcc Oscar Lambret Lille

    Lille

    Xavier Mirabelle, MD,PhD

    Recruiting

  • C H U Dupuytren Limoges

    Limoges

    Muriel Mathonnet, Md,PhD

    Recruiting

  • Hospices Civils de Lyon (Pierre Bénite,Edouard Herriot, La Croix Rousse)

    Lyon

    Olivier Glehen, MD

    Recruiting

  • Aphm Hopital Nord

    Marseille

    Recruiting

  • Hopital St Eloi Chu Montpellier

    Montpellier

    Recruiting

  • Icm - Montpellier

    Montpellier

    Recruiting

  • Chu de Nantes :Site Hôtel-Dieu- Hme

    Nantes

    Recruiting

  • Chu Nimes

    Nîmes

    Recruiting

  • Hu Est Parisien Site St Antoine Aphp

    Paris

    Recruiting

  • Hu Paris Centre Site Cochin Aphp

    Paris

    Recruiting

  • Hu Paris Sud Site Kremlin Bicetre Aphp

    Paris

    Recruiting

  • Hu Saint Louis Site Saint Louis Aphp

    Paris

    Recruiting

  • Hopital Haut-Leveque - Chu - Pessac

    Pessac, 33604

    0556556565

    Recruiting

  • Hopital Robert Debre Chu Reims

    Reims

    Recruiting

  • Chru Rennes Site Pontchaillou

    Rennes

    Recruiting

  • Hopital Charles Nicolle Chu Rouen

    Rouen

    Recruiting

  • Hus/Hop Hautepierre

    Strasbourg

    Recruiting

  • Hopital Purpan Chu

    Toulouse

    Recruiting

  • Chu de Tours

    Tours

    Recruiting

  • Institut de Cancerologie de Lorraine

    Vandœuvre-lès-Nancy

    Recruiting

  • Institut Gustave Roussy

    Villejuif

    Recruiting

Other trials in France

About this study

Official title: National Oesophageal and Gastric Carcinomas Data Base Construction: the FREGAT (French EsoGastric Tumours) Data Base

This retrospective study aims at evaluating the outcomes of gastrointestinal stromal tumor after surgery.

Keywords
Esophagus, Surgery
Medical subject headings
Esophageal Diseases

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. DIsease free survival

    Measured: 5 year disease free survival

Secondary outcomes (5)

  1. overall survival

    Measured: 5 year overall survival

  2. recurrence rate

    Measured: 5 year recurrence rate

  3. Total number of patients with complications

    Measured: from the time between inclusion and occurrence of the event, for the duration of 3 years

  4. Total number of complications

    Measured: from the time between inclusion and occurrence of the event, for the duration of 3 years

  5. Death

    Measured: from the time between inclusion and occurrence of the event, for the duration of 3 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted18 Aug 2015 (estimated)
  2. Study startJun 2014
  3. Primary completionMay 2027 (estimated)
  4. Study completionMay 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
15,000 participants (estimated)
Target duration
13 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT02526095
Sponsor's protocol ID
2013_33
Other IDs
2013-A01281-44
Acronym
FREGAT
Status last verified
Sep 2020
First submitted
13 Aug 2015
Last updated
14 May 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Mariette C, Renaud F, Piessen G, Gele P, Copin MC, Leteurtre E, Delaeter C, Dib M, Clisant S, Harter V, Bonnetain F, Duhamel A, Christophe V, Adenis A; Fregat Working Group. The FREGAT biobank: a clinico-biological database dedicated to esophageal and gastric cancers. BMC Cancer. 2018 Feb 6;18(1):139. doi: 10.1186/s12885-018-3991-8.

    PubMed 29409462

Questions about this trial

What is this clinical trial studying?

An observational study of Esophageal Disease, run by University Hospital, Lille at 31 sites in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 31 sites in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Guillaume Piessen, MD, PhD (+3320444407, guillaume.piessen@chru-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

DIsease free survival (time frame: 5 year disease free survival). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02526095, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026; AzTrials last refreshed its copy on 3 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in